Yahoo Finance EMVision Medical Devices Full Year 2023 Earnings: AU$0.05 loss per share (vs AU$0.081 loss in FY 2022)
EMVision Medical Devices (ASX:EMV) Full Year 2023 Results
Key Financial Results
Revenue: AU$7.09m (up 63% from FY 2022).
Net loss: AU$3.87m (loss narrowed by 37% from FY 2022).
AU$0.05 loss per share (improved from AU$0.081 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
EMVision Medical Devices Earnings Insights
Looking ahead, revenue is expected to decline by 4.2% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in Australia are expected to grow by 11%.
Performance of the Australian Medical Equipment industry.
The company's shares are up 10% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for EMVision Medical Devices (of which 1 shouldn't be ignored!) you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
